BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6600
- TODAY'S CHANGE (%)0.0400 (6.4516%)
- Bid / Lots0.6501/ 3
- Ask / Lots0.6600/ 10
- Open / Previous Close0.6500 / 0.6200
- Day Range
- 52 Week Range
- Volume85,856
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 4358 | 0.65 |
| 09:34 ET | 5400 | 0.6501 |
| 09:36 ET | 16499 | 0.65 |
| 09:50 ET | 5100 | 0.65 |
| 09:52 ET | 1000 | 0.650001 |
| 09:56 ET | 2540 | 0.65 |
| 09:59 ET | 599 | 0.6595 |
| 10:01 ET | 14742 | 0.6595 |
| 10:06 ET | 3000 | 0.666054 |
| 10:10 ET | 8000 | 0.666054 |
| 10:12 ET | 4279 | 0.659499 |
| 10:17 ET | 5803 | 0.659501 |
| 10:19 ET | 9103 | 0.65 |
| 10:33 ET | 1710 | 0.6501 |
| 10:37 ET | 3000 | 0.658465 |
| 10:42 ET | 600 | 0.66 |
Sep 17, 2024
BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection, from 1:01PM ET on Tuesday Sep 17, 2024 by Dow Jones
1:01PM ET on Tuesday Sep 17, 2024 by Dow Jones
Sep 4, 2024
DJ BioLine RX Initiated at Buy by Jones Trading, from 12:15PM ET on Wednesday Sep 04, 2024 by Dow Jones
12:15PM ET on Wednesday Sep 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 53.1M | -0.9x | --- |
Kronos Bio Inc | 57.3M | -0.6x | --- |
LAVA Therapeutics NV | 45.2M | -1.9x | --- |
Kezar Life Sciences Inc | 41.6M | -0.5x | --- |
Armata Pharmaceuticals Inc | 78.9M | -1.2x | --- |
Atara Biotherapeutics Inc | 55.0M | -0.2x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $53.1M |
|---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 80.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.46 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | 4.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
